Management Team

Gisela Mautner

Dr Gisela Mautner 

Chief Executive Officer and Managing Director

MD-PhD (TU-LMU Munich), MPH (Harvard), MBA (Kellogg), FACPE (Australia), GAICD

Dr Gisela Mautner has more than 20 years of extensive leadership experience in global pharmaceutical organisations, including operational, medical and scientific advisory roles across multiple therapeutic areas. During her career she held senior positions at global pharmaceutical companies like MSD (Merck), Bayer and Amgen in Germany as well as Australia.

She holds a Doctor of Medicine degree and a PhD from Germany, a Master of Public Health (MPH) from Harvard University, and a Master of Business Administration (MBA) from Northwestern University of Chicago.

She is a Graduate of the Australian Institute of Company Directors (GAICD).

Gisela was appointed Chief Executive Officer and Managing Director of Noxopharm in 2022, previously serving as Chief Medical Officer since 2019.

Read more
Jeanette Bell

Dr Jeanette Bell 

Chief Operating Officer

BMedSc, MScM, PhD

Jeanette has been engaged in the private, public and corporate healthcare sectors for over three decades, including a successful 15-year period at Lilly Pharmaceuticals.

Her extensive management experience in large pharmaceutical companies, from drug development and clinical trials through to drug launches and commercialisation, gives her a deep understanding of the mechanisms required to progress assets through the drug development pipeline to market.

Jeanette has held international leadership positions across Australia, Europe and Asia, and has deep insights into the intricate frameworks required to deliver a strategic vision across multiple regions and stakeholder groups.

Jeanette holds a PhD (Computer Science) from UTS Sydney, a Master of Science Management (UTS) and a Bachelor of Medical Science (UTS), and as well as operations-related qualifications in portfolio management and Six Sigma methodologies.

Read more
John Wilkinson

Dr John Wilkinson 

Chief Scientific Officer - Oncology

BSc Hons, PhD

John brings over 30 year’s scientific leadership in oncology and virology from biotech, pharmaceutical and research settings in Australia and the UK.

He managed high performing teams with a focus on the development of small molecules to target viruses and cancer through preclinical and clinical stages, and has extensive experience in drug development, formulation, regulatory and manufacture. Over the course of his career, John has formed relationships with key players in pharma, academia and clinical research and has proven success in leading complex projects to bring products through development and into the clinic.

John’s career includes positions with Biotron Ltd., University of NSW, St Vincent’s Centre for Applied Medical Research, Westmead Millennial Institute, Sydney Children’s’ Hospital and Chelsea & Westminster Hospital in London and Wellcome Research Laboratories in the UK.

John holds a PhD in immunology from the University of NSW and a Bachelor of Science from the University of Portsmouth in the UK.
Read more

Dr Olivier Laczka 

Chief Scientific Officer - Inflammation

BSc, MSc, PhD

Olivier is a highly experienced leader in drug development, biopharmaceuticals, biotechnology and diagnostics.

His skillset includes immunoassays, patents, scientific writing and grants, as well as people and project management. Olivier brings to Noxopharm diverse experience in generating both intellectual property and research funding, along with managing effective collaborations with commercial organisations, academic institutions, governments, and private entities at the international level.

Prior to joining the company in 2018, Olivier was a senior research scientist with 3M, PriME Biologics and AEGROS Innovations. He also held various roles in academic institutions such as UTS Sydney, Macquarie University, and the Institute of Microelectronics of Barcelona.

Olivier holds a PhD in Biotechnology from the Autonomous University of Barcelona, a Master of Applied Biotechnology and Microbiology from Ecole Supérieure d’Ingénieur de Luminy in Marseille, and a Bachelor degree in Biology and Environmental Sciences from the Institut Universitaire de Technology in Nantes.

Read more
Shawn Van Boheemen

Shawn Van Boheemen 

Chief Financial Officer


Shawn has 30 years' experience in commercial finance leadership positions across a range of healthcare, biotech, manufacturing, service-based and financial services industries.

His experience includes Australian ASX and ASIC reporting, SEC reporting in the US, compliance and regulatory affairs, audit (internal and external), taxation, business and financial analytics, intellectual property protection, and regulatory and financial reporting both in Australia and the US.

He has worked in senior financial positions for several Australian and multinational organisations, including Covance, Unomedical, M.D. Sass and New York Life Insurance.

Shawn is currently the CFO for Noxopharm Limited (NOX) and CFO/Company Secretary for Audio Pixels Holdings Limited (AKP).

Shawn holds a Master of Commerce degree with a major in Accounting (UWS), a Bachelor of Business degree in Accounting and Commercial Law (UWS), and is a Fellow of the Australian Society of Certified Practising Accountants as well as a Justice of the Peace in NSW.

Read more